Lapatinib Tablets 250 mg
LAPALIEVA 250 MG (Lapatinib Tablets 250 mg) is a targeted anticancer medicine used in the treatment of certain types of HER2-positive breast cancer. It contains Lapatinib, an advanced tyrosine kinase inhibitor (TKI) that works by blocking specific proteins responsible for the growth and spread of cancer cells. This targeted therapy is widely prescribed by oncologists for patients with advanced, metastatic, or treatment-resistant breast cancer.
Breast cancer remains one of the most commonly diagnosed cancers worldwide. In some patients, cancer cells produce excessive amounts of a protein known as Human Epidermal Growth Factor Receptor 2 (HER2). This protein promotes rapid cancer cell growth and increases the aggressiveness of the disease. LAPALIEVA 250 MG helps control this process by targeting HER2 and Epidermal Growth Factor Receptor (EGFR), thereby slowing cancer progression and supporting long-term disease management.
Unlike traditional chemotherapy, Lapatinib specifically targets cancer-related pathways, making it an important component of modern precision oncology treatment. It is often used in combination with other anticancer medicines to improve treatment outcomes and help patients achieve better disease control.
LAPALIEVA 250 MG is commonly prescribed for:
• HER2-positive metastatic breast cancer
• Advanced breast cancer
• Hormone receptor-positive and HER2-positive breast cancer
• Recurrent breast cancer
• Combination targeted therapy protocols
• Long-term oncology treatment programs
The medicine is manufactured under strict pharmaceutical quality standards to ensure safety, efficacy, and consistent therapeutic performance. It should only be used under the supervision of qualified healthcare professionals experienced in oncology and cancer treatment.
Patients receiving LAPALIEVA 250 MG may require regular medical monitoring, imaging studies, liver function assessments, and cardiac evaluations throughout therapy. These assessments help doctors evaluate treatment effectiveness and identify any potential complications early.
Because of its proven effectiveness in HER2-positive breast cancer treatment, LAPALIEVA 250 MG has become an important part of modern targeted cancer therapy and personalized oncology care.
View Details
Letrozole Tablets IP 2.5 mg
LETROLIEVA 2.5 MG (Letrozole Tablets IP 2.5 mg) is a prescription medicine used primarily in the treatment of hormone receptor-positive breast cancer in postmenopausal women. It contains Letrozole 2.5 mg, a highly effective aromatase inhibitor that helps reduce estrogen levels in the body. Since certain breast cancers depend on estrogen for growth and survival, lowering estrogen levels can help slow or stop the growth of cancer cells.
Breast cancer is one of the most common cancers affecting women worldwide. In many cases, cancer cells possess hormone receptors that respond to estrogen. LETROLIEVA 2.5 MG works by blocking the aromatase enzyme, which is responsible for producing estrogen in postmenopausal women. By reducing estrogen production, the medicine helps prevent cancer cells from receiving the hormonal stimulation they need to grow.
Letrozole is widely used as part of modern hormone therapy and targeted breast cancer treatment programs. It may be prescribed after surgery, radiation therapy, chemotherapy, or as a long-term maintenance treatment to reduce the risk of cancer recurrence.
LETROLIEVA 2.5 MG is commonly prescribed for:
• Hormone Receptor-Positive Breast Cancer
• Early-Stage Breast Cancer
• Advanced Breast Cancer
• Metastatic Breast Cancer
• Adjuvant Hormonal Therapy
• Long-Term Breast Cancer Management
• Postmenopausal Breast Cancer Treatment
In addition to its role in oncology, Letrozole may sometimes be prescribed for fertility-related conditions under specialist supervision. However, its primary use remains breast cancer treatment and management.
Manufactured under stringent pharmaceutical quality standards, LETROLIEVA 2.5 MG is designed to provide consistent therapeutic performance and reliable treatment outcomes. The medicine should only be used under the supervision of qualified healthcare professionals experienced in oncology and hormone therapy.
Patients receiving Letrozole therapy may require regular medical monitoring, bone density assessments, cholesterol evaluations, and routine follow-up visits to ensure safe and effective treatment.
Due to its proven effectiveness in reducing breast cancer recurrence and supporting long-term disease control, LETROLIEVA 2.5 MG has become an essential medicine in modern breast cancer care.
View Details
Anastrozole Tablets 1 mg
ANALIEVA 1 MG (Anastrozole Tablets 1 mg) is a prescription hormone therapy medicine used for the treatment and management of hormone receptor-positive breast cancer in postmenopausal women. It contains Anastrozole 1 mg, a highly effective aromatase inhibitor that helps reduce estrogen production in the body. Since many breast cancers depend on estrogen to grow and spread, lowering estrogen levels can help slow cancer progression and reduce the risk of recurrence.
Breast cancer is one of the most common cancers affecting women globally. In hormone receptor-positive breast cancer, cancer cells use estrogen as a growth signal. ANALIEVA 1 MG works by blocking the aromatase enzyme, which is responsible for converting androgens into estrogen in postmenopausal women. By significantly reducing estrogen levels, the medicine helps prevent cancer cells from receiving the hormonal stimulation they need to survive and multiply.
Anastrozole has become an important part of modern breast cancer treatment protocols and is widely recommended by oncologists for both early-stage and advanced hormone-sensitive breast cancer. It is often prescribed after surgery, radiation therapy, or chemotherapy to support long-term disease control and improve treatment outcomes.
ANALIEVA 1 MG is commonly prescribed for:
• Hormone Receptor-Positive Breast Cancer
• Early-Stage Breast Cancer
• Advanced Breast Cancer
• Metastatic Breast Cancer
• Adjuvant Hormonal Therapy
• Long-Term Breast Cancer Management
• Postmenopausal Breast Cancer Treatment
The medicine is manufactured under strict pharmaceutical quality standards to ensure safety, efficacy, and consistent therapeutic performance. It should only be used under the supervision of qualified healthcare professionals experienced in oncology and hormonal cancer therapy.
Patients receiving ANALIEVA 1 MG may require regular medical monitoring, bone density assessments, cholesterol evaluations, and routine follow-up visits to ensure treatment effectiveness and manage potential side effects.
Due to its proven effectiveness in reducing breast cancer recurrence and supporting long-term disease management, ANALIEVA 1 MG remains an essential medicine in modern breast cancer care.
View Details
Palbociclib Capsules 125mg
PALBOLIEVA 125 mg contains Palbociclib, an oral cyclin-dependent kinase (CDK) 4/6 inhibitor. It inhibits CDK4 and CDK6, causing cell-cycle arrest in the G1 phase, thereby slowing the growth of hormone receptor–positive breast cancer cells.
View Details
Palbolieva Capsules 100mg
PALBOLIEVA 100 mg contains Palbociclib, an oral cyclin-dependent kinase (CDK) 4/6 inhibitor. It works by inhibiting CDK4 and CDK6, leading to cell-cycle arrest in the G1 phase and suppression of cancer cell proliferation, particularly in hormone receptor–positive breast cancer.
View Details
Fulvestrant Injection 250 MG
Falsolieva 250 mg contains Fulvestrant, a hormonal anticancer medicine classified as a Selective Estrogen Receptor Degrader (SERD). It works by binding to estrogen receptors and causing their degradation, thereby blocking estrogen-driven growth of hormone-dependent breast cancer cells.
View Details
